

```

cgttatgggt tgaagtaatc cggactagcg cagccggggt taaacgcagg cttectgatt      600
gcctgggagg cctgttcata cccgtaggcg accgacagca acgtggcttc gctcaaattt      660
ttcccataga agtgaacggc tgtcggcatc ccttcgtcgt ccatgcccga tggatggag      720
ataccgggat aaccggccac cgccgagtag tagtaactgt atgagtgaat gttggacatc      780
attgcatcaa gcttatgctc ggccagcggc ttatcgatgg tgcttttgaa aatcggggccg      840
atggcagccc ataactcatt gcgcgcctca tcatgatata ccatcccgtt gatcatgggtg      900
agcatctgtt gatccggcac acccggaccg ctgttgcgct cgttgaattc aatcagctca      960
gccagcgact tcaccggcaa gcctgcccgt ccggccagggt aggtctcaag ctggtgttta     1020
acgtccgata acaacgcgtc gttatatgtt tcatgggttt cgtacgggac gccctcaccc     1080
agttgaccca cgggtaccaa tgtcgcgccc ttgcctcgca gcaacgtaat ggcatcctcg     1140
aagtgtcstt gtcggctttt ttccgcccgt cgttggcatc ttctacagat aactcaggca     1200
acggcgata accgatgcgc ttgcccacca aggcgtcagg cttgattccc tgggtgtagc     1260
ggttggatat cgtcatcgca tccagtgtt gcgcgcgatn acgcacgtta cgggtgaagg     1320
tgcccacgt gtcctggcgg gaactggtca tcacccttcg gtactcacta atccttcggt     1380
cggtttgaaa ccaataacac cgttgtaagc cgccggcgta atgattgaac cattgggttc     1440
gacccccaat gccaagggca caatcccttg tgcaacggct accgcagagc ccgtactcga     1500
g

```

```

<210> 30
<211> 1752
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> SITE
<222> (1099)
<223> n equals a,t,g, or c

```

```

<400> 30
aaggtagcgc tgcaggtacc ggtccggaat tcccgggtcg acccagcgt ccgtccagga      60
cagagagtgc acaaactacc cagcacagcc ccctccgccc cctctggagg ctgaagaggg     120
attccagccc ctgccacca cagacacggg ctgactgggg tgtctgcccc ccttgggggg     180
gggcagcaca gggcctcagg cctgggtgcc acctggcacc tagaagatgc ctgtgccctg     240
gttcttgctg tccttggcac tgggcccgaag ccagtggtc ctttctcttg agaggcttgt     300
ggggcctcag gacgctaccc actgctctcc gggcctctcc tgccgcctct gggacagtga     360
catactctgc ctgcttgggg acatcgtgcc tgctccgggc ccctgtctgg cgcctacgca     420
cctgcagaca gagctgggtg tgaggtgcca gaaggagacc gactgtgacc tctgtctgcg     480
tgtggmtgtc cacttggccg tgcatgggca ctgggaagag cctgaagatg aggaaaagtt     540
tgaggagaca gctgacttag ggggtggagga gcctaggaat gcctctctcc aggcccaagt     600
cgtgctctcc ttccaggcct accctactgc ccgctgcgtc ctgctggagg tgcaagtgcc     660
tgctgccctt gtgcagtttg gtcagtctgt gggctctgtg gtatatgact gcttcgaggg     720
tgccctaggg agtgaggtac gaatctgggt ctatactcag ccaggtacg agaaggaayt     780
caaccacaca cagcagctgc ctgactgcag ggggctcgaa gtctggaaca gcatcccag     840
ctgctggggc ctgccctggc tcaacgtgtc agcagatggg gacaacgtgc atctggttct     900
gaatgtctct gaggagcagc acttcggcct ctccctgtac tggaatcagg tccaggggcc     960
cccaaaaccc cgggtggcaca aaaacctgac tggaccgcag atcattacct tgaaccacac     1020
agacctgggt ccctgcctct gtattcaggt gtggcctctg gaacctgact ccgttagacg     1080
aacatctgcc ccttcaggna ggacccccgc gcacaccaga acctctggca agccgcccga     1140
ctgcgactgc tgaccctgca gagctggctg ctggacgcac cgtgctcgtg gcccgagaa     1200
gcggcactgt gctggcgggc tccgggtggg gacccctgcc agccactggg cccaccgctt     1260
tcctgggaga aygtcactgt ggacaagggt ctcgagttcc cattgctgaa aggccaccct     1320
aacctctgtg ttcaggtgaa cagctcggag aagctgcagc tgcaggagtg cttgtgggct     1380
gactccctgg ggcctctcaa agacgatgtg ctactgttgg agacacgagg ccccaggac     1440
aacagatccc tctgtgcctt ggaacccagt ggctgtactt cactaccag caaagcctcc     1500
acgagggcag ctgccttgg agagtactta ctacaagacc tgcagtcagg ccagtgtctg     1560
cagctatggg acgatgactt gggagcgcta tgggcctgcc ccatggacaa atacatccac     1620
aagcgtggg ccctcgtgtg gctggcctgc ctactctttg cctgcgcttt ccctcactct     1680
ccttctcaaa aaggatcacg cgaaagggtg gctgaggctc ttgaaacagg acgtccgctc     1740
gggggcggcc gc

```

```

<210> 31
<211> 2152

```

<212> DNA

<213> Homo sapiens

<400> 31

ccgctttgtt	ctccagatgt	gaatagctcc	actataccag	cctcgtcttc	cttccggggg	60
acaacgtggg	tcagggcaca	gagagatatt	taatgtcacc	ctcttggggc	tttcatggga	120
ctccctctgc	cacatttttt	ggaggttggg	aaagttgcta	gaggcttcag	aactccagcc	180
taatggatcc	caaactcggg	agaatggctg	cgccctgct	ggctgtgctg	ctgctgctgc	240
tgctggagcg	cggcattgtc	tcctcaccc	ccccgcccc	ggcgtgtgta	gagaaagtct	300
tccagtacat	tgacctccat	caggatgaat	ttgtgcagac	gctgaaggag	tgggtggcca	360
tcgagagcga	ctctgtccag	cctgtgcctc	gcttcagaca	agagctcttc	agaatgatgg	420
ccgtggctgc	ggacacgctg	cagcgccctg	gggcccgtgt	ggcctcgggt	gacatgggtc	480
ctcagcagct	gcccgatggg	cagagtcttc	caatacctcc	cgctacccct	gccgaactgg	540
ggagcgatcc	cacgaaaggc	accgtgtgct	tctacggcca	cttggacgtg	cagcctgctg	600
accggggcga	tgggtggctc	acggacccct	atgtgctgac	ggaggtagac	gggaaacttt	660
atggacgagg	agcgaccgac	aacaaaggcc	ctgtcttggc	ttggatcaat	gctgtgagcg	720
ccttcagagc	cctggagcaa	gatcttcctg	tgaatatcaa	attcatcatt	gaggggatgg	780
aagaggctgg	ctctgttgcc	ctggaggaac	ttgtggaaaa	agaaaaggac	cgattcttct	840
ctggtgtgga	ctacattgta	atttcagata	acctgtggat	cagccaaagg	aagccagcaa	900
tcacttatgg	aaccgggggg	aacagctact	tcatggtgga	ggtgaaatgc	agagaccagg	960
atthttcactc	aggaaccttt	ggtggcatcc	ttcatgaacc	aatggctgat	ctggttgctc	1020
ttctcggtag	cctggtagac	tcgtctgggt	atatcctggg	ccctggaatc	tatgatgaag	1080
tggttcctct	tacagaagag	gaaataaata	catacaaagc	catccatcta	gacctagaag	1140
aataccggaa	tagcagccgg	gttgagaaat	ttctgttcga	tactaaggag	gagattctaa	1200
tgcacctctg	gaggtaccca	tctcttttcta	ttcatgggat	cgagggcgcg	tttgatgagc	1260
ctggaactaa	aacagtcata	cctggccgag	ttataggaaa	atthttcaatc	cgtctagtcc	1320
ctcacatgaa	tgtgtctgcg	gtggaaaaac	aggtgacacg	acatcttgaa	gatgtgttct	1380
ccaaaagaaa	tagttccaac	aagatgggtg	tttccatgac	tctaggacta	cacccgtgga	1440
ttgcaaatat	tgatgacacc	cagtatctcg	cagcaaaaag	agcgatcaga	acagtgtttg	1500
gaacagaacc	agatatgatc	cgggatggat	ccaccattcc	aattgcaaaa	atgttccagg	1560
agatcgctcca	caagagcggt	gtgctaattc	cgctgggagc	tgttgatgat	ggagaacatt	1620
cgcagaatga	gaaaatcaac	aggtggaact	acatagaggg	aaccaaatta	tttgctgcct	1680
ttttcttaga	gatggcccgag	ctccattaat	cacaagaacc	ttctagtctg	atctgatcca	1740
ctgacagatt	cacctcccc	acatccctag	acagggatgg	aatgtaaata	tccagagaat	1800
ttgggtctag	tatagtacat	tttcccttcc	atthaaaatg	tcttgggata	tctggatcag	1860
taataaaaata	tttcaaaggc	acagatgttg	gaaatgggtt	aaggtcccc	actgcacacc	1920
ttcttcaagt	catagctgct	tgcagcaact	tgatttcccc	aagtcctgtg	caatagcccc	1980
aggattggat	tccttccaac	cttttagcat	atctccaacc	ttgcaatttg	attggcataa	2040
tcaactccgg	ttgcttttcta	ggtcctcaag	tgctcgtgac	acataatcat	tccatccaat	2100
gatcgccctt	gctttaccay	tctttccttt	tatcttatta	ataaaaatgt	tg	2152

<210> 32

<211> 1757

<212> DNA

<213> Homo sapiens

<400> 32

aggctttcca	cccagaccgt	caacttcggg	acagtggggg	agacgggtcac	ccttcacatc	60
tgcccagaca	gggatgggga	tgaggcggga	cagcctgatg	ctgctgccat	ggtggcttgg	120
ggcagcgggg	agaaaggagt	gtcacaggga	gcagctcgtg	gctgcagtgg	aagtcactga	180
gcaagagact	aaagtcccca	agaaaaccgt	catcatagaa	gagaccatca	ccactgtggt	240
gaagagccca	cgtggccaac	gacggtyccc	cagcaagtcc	ccctcccgct	caccttccc	300
ctgctctgcc	agcccgtgta	ggccaggcct	actggcccc	gacctgctgt	acctgccagg	360
tgctggccag	ccccgcaggc	cggargcaga	accaggccag	aagcccttgg	tgcccacact	420
gtatgtgacg	gaggccgagg	cccactctcc	agctctgccc	ggactctcgg	ggccccagcc	480
caagtgggtg	gaggtggagg	agaccattga	agtccgggtg	aagaagatgg	gcccgcaggg	540
tgtgtctccc	accacagagg	tgcccaggag	ctcatcgggg	catctcttca	cactgcccgg	600
tgcgaccccc	ggaggggacc	ccaattccaa	caactccaac	aacaagctgc	tggcccagga	660
ggcctggggc	cagggcacag	ccatggtcgg	cgtcagagag	ccccttgtct	tccgcgtgga	720
tgccagaggc	agtgtggact	gggctgcttc	tggcatgggc	agcctggagg	aggagggcac	780
catggaggag	gcgggagagg	aagaggggga	agacggagac	gccttgtgta	cggaggagtc	840
ccaggacaca	cacagccttg	gggatcgtga	ccccaaagatc	ctcacgcaca	acggccgcat	900
gctgacactg	gctgacctgg	aagattacgt	gcctggggaa	ggggagacct	tccactgtgg	960

IgG) can also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995).)

Similarly, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion
5 proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP-A 0232 262.) Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified,
10 would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, D. Bennett et al., J. Molecular Recognition 8:52-58 (1995); K. Johanson et al., J. Biol.
15 Chem. 270:9459-9471 (1995).)

Moreover, the polypeptides of the present invention can be fused to marker sequences, such as a peptide which facilitates purification of the fused polypeptide. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue,
20 Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope derived from the influenza hemagglutinin protein. (Wilson et al., Cell 37:767
25 (1984).)

Thus, any of these above fusions can be engineered using the polynucleotides or the polypeptides of the present invention.

Vectors, Host Cells, and Protein Production

30 The present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral

vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

5 The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

10 The polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the E. coli lac, trp, phoA and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding
15 portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin
20 resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in E. coli and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as E. coli, Streptomyces and Salmonella typhimurium cells; fungal cells, such as yeast cells; insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as
25 CHO, COS, 293, and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and
30 ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia Biotech, Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1

and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Other suitable vectors will be readily apparent to the skilled artisan.

Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, or other methods. Such methods
5 are described in many standard laboratory manuals, such as Davis et al., Basic Methods In Molecular Biology (1986). It is specifically contemplated that the polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector.

10 A polypeptide of this invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most
15 preferably, high performance liquid chromatography ("HPLC") is employed for purification.

Polypeptides of the present invention, and preferably the secreted form, can also be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical
20 synthetic procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect, and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also
25 include an initial modified methionine residue, in some cases as a result of host-mediated processes. Thus, it is well known in the art that the N-terminal methionine encoded by the translation initiation codon generally is removed with high efficiency from any protein after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some
30 proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

In addition to encompassing host cells containing the vector constructs discussed herein, the invention also encompasses primary, secondary, and immortalized host cells of vertebrate origin, particularly mammalian origin, that have been engineered to delete or replace endogenous genetic material (e.g., coding
5 sequence), and/or to include genetic material (e.g., heterologous polynucleotide sequences) that is operably associated with the polynucleotides of the invention, and which activates, alters, and/or amplifies endogenous polynucleotides. For example, techniques known in the art may be used to operably associate heterologous control regions (e.g., promoter and/or enhancer) and endogenous polynucleotide sequences
10 via homologous recombination (see, e.g., U.S. Patent No. 5,641,670, issued June 24, 1997; International Publication No. WO 96/29411, published September 26, 1996; International Publication No. WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); and Zijlstra et al., Nature 342:435-438 (1989), the disclosures of each of which are incorporated by reference in their
15 entireties).

Uses of the Polynucleotides

Each of the polynucleotides identified herein can be used in numerous ways as
20 reagents. The following description should be considered exemplary and utilizes known techniques.

The polynucleotides of the present invention are useful for chromosome identification. There exists an ongoing need to identify new chromosome markers, since few chromosome marking reagents, based on actual sequence data (repeat
25 polymorphisms), are presently available. Each polynucleotide of the present invention can be used as a chromosome marker.

Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the sequences shown in SEQ ID NO:X. Primers can be selected using computer analysis so that primers do not span more than one predicted
30 exon in the genomic DNA. These primers are then used for PCR screening of somatic-cell-hybrids-containing individual human chromosomes. Only those hybrids